This suggests that concomitant activation of CD4+ T cells by a neoantigen vaccine platform not only improves priming of CD8 epitope responses but also plays a vital role in optimizing the trafficking of neoantigen-specific CD8+ T cells into the tumor. This evidence concerns the gene CD8A and neoplasm.